ArticleInfection and immunity2007
Murine aerosol challenge model of anthrax.
Article in Infection and immunity, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 67 citations in OpenAlex.
- Mechanistic within-host mathematical model of inhalational anthrax.PLoS computational biology · 2025Article
- A Lyophilizable Nanoparticle Anthrax Vaccine Targeting the Loop-Neutralizing Determinant in Protective Antigen fromMicroorganisms · 2025Article
- Bacillus cereus biovar anthracis causes inhalational anthrax-like disease in rabbits that is treatable with medical countermeasures.PLoS neglected tropical diseases · 2025Article
- Toxin and capsule production by Bacillus cereus biovar anthracis influence pathogenicity in macrophages and animal models.PLoS neglected tropical diseases · 2024Article
- RapidAntimicrobial agents and chemotherapy · 2024Article
- Lysins as a powerful alternative to combat Bacillus anthracis.Applied microbiology and biotechnology · 2024Review
- Anthrax lethal toxin and tumor necrosis factor-α synergize on intestinal epithelia to induce mouse death.Protein & cell · 2024Article
- Teixobactin Provides Protection against Inhalation Anthrax in the Rabbit Model.Pathogens (Basel, Switzerland) · 2020Article
- Current Status and Trends in Prophylaxis and Management of Anthrax Disease.Pathogens (Basel, Switzerland) · 2020Review
- Article
- Characterisation of the antibacterial properties of the recombinant phage endolysins AP50-31 and LysB4 as potent bactericidal agents against Bacillus anthracis.Scientific reports · 2018Article
- Bacillus anthracis Spore Surface Protein BclA Mediates Complement Factor H Binding to Spores and Promotes Spore Persistence.PLoS pathogens · 2016Article
- The Exosporium Layer of Bacterial Spores: a Connection to the Environment and the Infected Host.Microbiology and molecular biology reviews : MMBR · 2015Review
- Article
- Advax-adjuvanted recombinant protective antigen provides protection against inhalational anthrax that is further enhanced by addition of murabutide adjuvant.Clinical and vaccine immunology : CVI · 2014Article
- Colonic immune suppression, barrier dysfunction, and dysbiosis by gastrointestinal bacillus anthracis Infection.PloS one · 2014Article
- Bacillus anthracis has two independent bottlenecks that are dependent on the portal of entry in an intranasal model of inhalational infection.Infection and immunity · 2013Article
- Transient lipopolysaccharide-induced resistance to aerosolized Bacillus anthracis in New Zealand white rabbits.Comparative medicine · 2013Article
- Pathology and pathophysiology of inhalational anthrax in a guinea pig model.Infection and immunity · 2013Article
- A New Murine Model for Gastrointestinal Anthrax Infection.PloS one · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
The availability of relevant and useful animal models is critical for progress in the development of effective vaccines and therapeutics. The infection of rabbits and non-human primates with fully virulent Bacillus anthracis spores provides two excellent models of anthrax disease. However, the high cost of procuring and housing these animals and the specialized facilities required to deliver fully virulent spores limit their practical use in early stages of product development. Conversely, the small size and low cost associated with using mice makes this animal model more practical for conducting experiments in which large numbers of animals are required. In addition, the availability of knockout strains and well-characterized immunological reagents makes it possible to perform studies in mice that cannot be performed easily in other species. Although we, along with others, have used the mouse aerosol challenge model to examine the outcome of B. anthracis infection, a detailed characterization of the disease is lacking. The current study utilizes a murine aerosol challenge model to investigate disease progression, innate cytokine responses, and histological changes during the course of anthrax after challenge with aerosolized spores. Our results show that anthrax disease progression in a complement-deficient mouse after challenge with aerosolized Sterne spores is similar to that described for other species, including rabbits and non-human primates, challenged with fully virulent B. anthracis. Thus, the murine aerosol challenge model is both useful and relevant and provides a means to further investigate the host response and mechanisms of B. anthracis pathogenesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.